ABVX Stock Summary and Trading Ideas (Abivax SA - American Depositary Shares | NASDAQ:ABVX)

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.

Abivax SA - American Depositary Shares trades on the NASDAQ stock market under the symbol ABVX.

As of December 26, 2024, ABVX stock price declined to $7.53 with 174,429 million shares trading.

ABVX has a beta of 0.51, meaning it tends to be less sensitive to market movements. ABVX has a correlation of 0.02 to the broad based SPY ETF.

ABVX has a market cap of $476.93 million. This is considered a Small Cap stock.

ABVX has underperformed the market in the last year with a price return of -33.2% while the SPY ETF gained +28.5%. ABVX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -33.4% and -12.2%, respectively, while the SPY returned +5.7% and +0.1%, respectively.

ABVX support price is $7.24 and resistance is $7.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABVX shares will trade within this expected range on the day.